Urocortin has been shown to produce vasodilatation in several arteries, but the precise mechanism of its action is still poorly understood. Here we demonstrate the role of store operated Ca 2ϩ entry (SOCE) regulated by Ca 2ϩ -independent phospholipase A 2 (iPLA 2 ) in phenylephrine hydrochloride (PE)-induced vasoconstriction, and we present the first evidence that urocortin induces relaxation by the modulation of SOCE and iPLA 2 in rat coronary artery. Urocortin produces an endothelium independent relaxation, and its effect is concentrationdependent (IC 50 Ϸ4.5 nmol/L). We show in coronary smooth muscle cells (SMCs) that urocortin inhibits iPLA 2 activation, a crucial step for SOC channel activation, and prevents Ca 2ϩ influx evoked by the emptying of the stores via a cAMP and protein kinase A (PKA)-dependent mechanism. Lysophophatidylcholine and lysophosphatidylinositol, products of iPLA 2 , exactly mimic the effect of the depletion of the stores in presence of urocortin. Furthermore, we report that long treatment with urocortin downregulates iPLA 2 mRNA and proteins expression in rat coronary smooth muscle cells. In summary, we propose a new mechanism of vasodilatation by urocortin which involves the regulation of iPLA 2 and SOCE via the stimulation of a cAMP/PKA-dependent signal transduction cascade in rat coronary artery.
C oronary artery smooth muscle cells (SMCs) regulate vascular tone influencing perfusion of the heart, peripheral resistance, and as a consequence heart function. Agonist induces a contraction of vascular SMCs by a rise in cytosolic free Ca 2ϩ concentration 1,2 because of a rapid Ca 2ϩ release by InsP 3 from intracellular stores and a transmembrane Ca 2ϩ influx through L-type voltage-dependent Ca 2ϩ channels or nonvoltage-gated channels such as store-operated Ca 2ϩ (SOC) channels. The relative contribution of each channel depends on the smooth muscle type. [2] [3] [4] The use of selective inhibitors of sarcoplasmic reticulum Ca 2ϩ -ATPase pump, as thapsigargin (TG), to activate SOC channels not only increases Ca 2ϩ influx but also enhances tone in a variety of SMCs. 3, 5 Recently we showed Ca 2ϩ -independent phospholipase A 2 (iPLA 2 ) to be a crucial determinant of storeoperated Ca 2ϩ entry (SOCE) . We demonstrated that the emptying of the stores activated iPLA 2 and its lysophospholipid products opened the SOC channels in aortic SMCs and nonexcitable cells. 6 -8 Thus iPLA 2 became a potential physiological target for regulation and fine-tuning of SOCE by other signaling cascades in SMCs.
A few years ago a new 40-aa peptide, urocortin, 9, 10 related to corticotropin-releasing factor (CRF) was described as a new player in cardiac control, 11, 12 and was proposed to protect cardiac myocytes during ischemia/reperfusion by downregulating iPLA 2 expression. 13, 14 Urocortin also emerged as a potent vasodilator peptide, and its mechanism of action appears to be complex, eg, vasodilatation has been reported to be both endothelium-dependent and independent in coronary artery 15, 16 and in other vessels. 16 -18 The vascular effects of urocortin are mediated by the CRF receptors 2 (CRF-R 2 ) which predominate in blood vessels. 12, 20 Binding of urocortin to CRF-R 2 increases its affinity for the Gs protein leading to the stimulation of cAMP/PKA pathway (for review see 12 ). Furthermore, cAMP-dependent protein kinase seems to modulate SOC channels in rabbit portal vein and in airway smooth muscle. 21, 22 Because urocortin modulates iPLA 2 activity and expression in cardiomyocytes, here we test whether urocortin could modulate iPLA 2 and in consequence SOCE that might regulate vascular tone of coronary artery. We unveil new important data of the mechanism by which urocortin relaxes rat coronary artery that include cAMP increase, iPLA 2 activity and expression modulation, and SOCE regulation in rat coronary SMCs.
Materials and Methods
Expanded details of all the methods are given in the supplemental data (available online at http://circres.ahajournals.org).
Cells and Arteries Preparation
Isolated rat coronary arteries were dissected from the heart, and SMCs were dispersed acutely or primary cultured as detailed in the online supplemental data. Isometric tension of rat coronary rings was measured in an organ chamber as previously described. 23
Measurement of Contractility in Arterial Rings
Rat coronary arteries were obtained from 2-month-old Wistar male rats. Arteries were cleaned of connective tissue, cut in rings (Ϸ2 mm), and mounted on a small-vessel myograph (JP Trading) to measure isometric tension connected to a digital recorder (Myodataq-2.01, Myodata-2.02 Multi-Myograph System).
Intracellular Ca 2؉ and Mn 2؉ Measurement
Dual-excitation imaging with fura-2 was used to measure cytosolic Ca 2ϩ and Mn 2ϩ changes in isolated SMCs as previously shown. 6 -8 
Molecular Studies
The activity of iPLA 2 was performed as described. 6 -8 The Kinase-Glo Luminescent Kinase Assay (Promega) was used to measure the PKA activity in coronary arteries after the indications of the manufacturers. Q-PCR, Western blot, and immunostaining were used to determine iPLA 2 expression in coronary SMCs.
Statistical Analysis
Group data are presented as meanϮSEM. Single or paired Student t test was used to determine the statistical significance of the obtained data. The difference was considered significant at PϽ0.01 and is marked by * in the figure.
Results

Urocortin Induces Dose-Dependent Relaxation of Rat Coronary Artery
The cumulative addition of urocortin to coronary artery precontracted with phenylephrine (PE) induced a concentration-dependent relaxation with an IC 50 Ϸ4.5 nmol/L, and maximum relaxation (Ϸ84%) was observed with 10 nmol/L urocortin ( Figure 1A ). Pretreatment of the arteries with L-NNA (100 mol/L) to inhibit nitric oxide synthase and endothelial-mediated relaxations induced a small and nonsignificant effect on urocortin dose-dependent relaxation ( Figure 1A , right panel). Meanwhile, urocortin (10 to 100 nmol/L) failed to relax the contraction induced by high K ϩ that involve L-type Ca 2ϩ channels pathway ( Figure 1B ). Furthermore, in presence of 500 nmol/L nifedipine (the selective inhibitor of L-type Ca 2ϩ channels), PE was able to produce a small but noticeable contraction that was relaxed by urocortin ( Figure 1C ) suggesting that urocortin-induced relaxation may occur independently of L-type Ca 2ϩ channels pathway.
Contribution of SOCE and iPLA 2 in PE-Induced Contraction
Agonist-induced contraction may involve nonvoltage-gated channels such as SOC channels; therefore the contribution of SOCE in coronary vascular tone was examined. Supplemental Figure Ia and Ib shows that PE-induced contraction was relaxed in a dose-dependent manner by 2 aminoethoxydiphenyl borate (2APB) and diethylstilbestrol (DES), inhibitors of SOC channels. 24 -27 Moreover and because we recently demonstrated that iPLA 2 is involved in SOCE, we found that inhibition of iPLA 2 by bromoenol lactone (BEL) relaxed gradually the artery (supplemental Figure Ic) . Although BEL is a potent iPLA 2 inhibitor, it also inhibits phosphatidate phosphohydrolase-1 (PAP-1). 28, 29 To block the activity of PAP-1, we pretreated the artery with 50 mol/L propanolol (PAP-1 specific inhibitor) and observed that propanolol failed to prevent BEL-induced relaxation confirming that PAP-1 is not involved in BEL effect (data not shown). In addition, in isolated fresh and cultured coronary SMCs, 2APB (75 mol/ L), DES (1 mol/L), and BEL (25 mol/L) inhibited TG-(2 mol/L) evoked Ca 2ϩ and Mn 2ϩ influx (supplemental Figure II ), like the data in aorta SMCs. 6, 7, 26 Importantly, when the contraction was induced by depolarization with high K ϩ , 2APB and BEL failed to relax the arteries (supplemental Figure III ).
Role of Store-Operated Ca 2؉ Entry in Urocortin-Induced Vasorelaxation
We then checked the role of SOC channels in urocortin effect on contraction. Figure 1D shows that the activation of SOCE with thapsigargin (TG, 10 mol/L) caused a contraction that was Ϸ93% relaxed by urocortin (10 nmol/L). Interestingly as shown in Figure 1E , TG-induced contraction was also relaxed Ϸ69% by nifedipine (1 mol/L) indicating a possible coactivation of SOC and L-type Ca 2ϩ channels as reported in other SMCs. 30 We further performed experiments in acutely dispersed and primary cultured rat coronary SMCs loaded with fura-2 to examine the effect of urocortin on TG-induced SOCE, and we observed that 10 minutes pretreatment with urocortin (10 nmol/L) prevented TG-induced Ca 2ϩ entry in fresh ( Figure 2B ) and cultured ( Figure 2C ) SMCs. It is important to note that urocortin effect was specific to Ca 2ϩ influx and did not alter TG-induced Ca 2ϩ release from the stores. This observation was confirmed when low concentration of ionomycin (100 nmol/L) was used to release Ca 2ϩ from the store as described. 31 ⌬ratio of ionomycin-induced Ca 2ϩ release was 0.23Ϯ0.01 in control versus 0.22Ϯ0.02 in urocortin treated SMCs (nϭ3 cultures). Furthermore, to exclude the influence of mechanisms that remove Ca 2ϩ from the cytoplasm, we used Mn 2ϩ -quench technique considered more direct measurement of ion channel mediated cation influx in intact cells. 6, 24, 32 Indeed, TG-induced Mn 2ϩ influx was also inhibited by urocortin in cultured ( Figure 2D ) and freshly isolated coronary SMCs ( Figure 2E ). All together suggest that urocortin modulates agonist-induced contraction of rat coronary artery apparently by SOCE regulation.
Urocortin Modulates iPLA 2 Activity and Expression in Coronary SMCs
Urocortin has been shown to protect the heart against ischemia-reperfusion by iPLA 2 downregulation, 13,14 thus we investigated whether urocortin could modulate iPLA 2 activity and expression in coronary artery. First, the activation of iPLA 2 by the depletion of Ca 2ϩ stores was determined in coronary SMCs, and consistent with previous reports, 6 -8,33 TG enhanced iPLA 2 activity in control coronary SMCs whereas in SMCs treated with urocortin (100 nmol/L) for 10 minutes the iPLA 2 activity was decreased about 80% ( Figure 3A ). In addition, the expression of iPLA 2 was assessed using real-time quantitative PCR. We observed a concentration-dependent decrease of iPLA 2 mRNA in SMCs treated 24 hours with urocortin and 100 nmol/L urocortin decreased 58% of iPLA 2 mRNA expression ( Figure 3B ). In addition Western blot study showed that 100 nmol/L urocortin also downregulated about 45% of iPLA 2 protein expression ( Figure 3C ). These results determine that urocortin can modulate iPLA 2 activity and expression in coronary SMCs that may be crucial for SOCE regulation.
The activation of iPLA 2 releases lysophospholipids and arachidonic acid 7,28 that can be metabolized by cyclooxygenase (COX). 34 To asses the role of COX pathway in urocortin response, PE was administrated in presence of indomethacin, a widely used COX inhibitor; and consistent with previous data in aorta, 35 PE in presence of 10 mol/L indomethacin induced a contraction of the same magnitude as in control ( Figure 3D ) which was relaxed by urocortin. These results discarded the involvement of COX regulation in urocortininduced relaxation of coronary artery as it was shown previously. 15
Urocortin Does Not Prevent SOCE Induced by iPLA 2 Products, Lysophosphatidylcholine, and Lysophosphatidylinositol
Lysophospholipids has been shown to activate ionic channels in a membrane-delimited fashion. 7, 36 Here, we checked whether lysophospholipids could mimic the effect of the depletion of the stores as we showed previously in aortic SMCs and rat basophilic leukemia (RBL) cells, 7 independently of urocortin's negative modulation of iPLA 2 . In coronary SMCs treated with urocortin, lysophosphatidylcholine (LPC, 300 nmol/L) and lysophosphatidylinositol (LPI, 300 nmol/L) evoked practically the same Ca 2ϩ (Figure 4A ,C) and Mn 2ϩ ( Figure 4B and 4D) influx as in untreated SMCs, which were inhibited by 2APB consistent with the involvement of the SOC channels. These results suggest that urocortin is not inhibiting directly SOC channels and confirm that its effect is through iPLA 2 .
Urocortin Inhibits SOCE and Contraction via a cAMP and PKA Signaling Pathway
We examined the effect of astressin, specific antagonist of CRF-R 2 , on contraction and SOCE. We observed that the application of astressin (500 nmol/L) blocked urocortin induced vasodilatation of coronary arteries (nϭ6, data not shown), and prevented the inhibition of TG-induced Ca 2ϩ and Mn 2ϩ influx by urocortin in SMCs as shown in Figure 2B , 2C, 2D, and 2E. CRF-R 2 is functionally linked to the Gs protein that activates adenylate cyclase and cAMP production. We tested the effect of dibutyril-cAMP (db-cAMP, a cell permeable analogue of cAMP) on contraction and on TG-induced Ca 2ϩ and Mn 2ϩ influx. We found that db-cAMP (300 to 500 mol/L) mimicked the effect of urocortin and induced a vasodilatation of PE-and TG-induced contraction ( Figure 5A and 5B), whereas in fura-2 loaded fresh and primary cultured SMCs, db-cAMP (300 to 500 mol/L) inhibited TG-induced Ca 2ϩ (Figure 5C and 5D) and Mn 2ϩ ( Figure 5E and 5F) influx, similar to that observed with urocortin. Importantly, db-cAMP inhibited iPLA 2 activity in the same way as urocortin ( Figure 6B ).
Protein kinase A (PKA) is the major target of cAMP signaling and is known to contribute to its impact on vascular Traces are for cells exposed to LPC alone (-Ucn); cells preincubated with 10 nmol/L urocortin for 10 minutes and then LPC (ϩUcn), and to cells treated with urocortin, LPC, and 2-APB (30 mol/L, ϩ2APB) added as indicated by the asterisk; nϭ30 to 110 from 3 cultures. B, Representative traces and summary data of Mn 2ϩ influxinduced fura-2 quenching in LPC-treated (300 nmol/L for 4 to 5 minutes before Mn 2ϩ was added) cultured SMCs under the same conditions as in A; nϭ40 to 60 from 3 cultures. C and D, Summary data of Ca 2ϩ and Mn 2ϩ influx induced by lysophosphatidylinositol (LPI, 300 nmol/L) treatment in similar conditions as in A and B, respectively; nϭ20 to 70 cells from 3 cultures. function. 37 Therefore, we investigated whether PKA is involved in urocortin action on coronary vasorelaxation and on SOCE. Figure 6A shows that urocortin (100 nmol/L) increased PKA activity equally in coronary artery stimulated or not with PE (1 mmol/L). Conversely the inhibition of PKA with KT5720 (1 mol/L) blocked urocortin-stimulated PKA activity ( Figure 6A ), and importantly it inhibited iPLA 2 activation ( Figure 6B ). Additionally, PKA blocking prevented urocortin-induced relaxation of PE-induced contraction ( Figure 6C ) and its inhibition of the store-operated Ca 2ϩ (Figure 5C and 5D ) and Mn 2ϩ influx ( Figure 5E and 5F) . Similar data were observed when H-89 (1 mol/L) was used to inhibit PKA (data not shown). Importantly, the downregulation of iPLA 2 protein expression ( Figure 7A ) by urocortin was reversed in SMCs pretreated previously with KT5720 (1 mol/L). The immunostaining approach (Figure 7B) shows the faint fluorescence in urocortin-treated cells and the difference observed in the merged images. These results suggest that urocortin regulates iPLA 2 activity and expression via a cAMP/PKA dependent mechanism which modulates SOCE in coronary artery.
All together, our data suggest a new mechanism of urocortin effect on Ca 2ϩ signaling and vascular tone that involves iPLA 2 and the SOC pathway summarized in Figure 8 . In this scenario, we suggest that an agonist that releases Ca 2ϩ from intracellular stores activates iPLA 2 and SOCE, which produces a vasoconstriction. We propose that the binding of urocortin to its receptor CRF-R 2 stimulates the cAMP/PKA signaling pathway which we showed can negatively modulates iPLA 2 , "shut down" the store-operated pathway, and in consequence induces the vasorelaxation of coronary artery.
Discussion
The major findings of this study describe a new mechanism for urocortin regulation of vascular tone that involves for the first time Ca 2ϩ -independent phospholipase A 2 and SOCE modulation. We have shown that urocortin induced an endothelium-independent relaxation in contrast with the data showed previously where the potency of urocortin was proposed to decrease in the endothelium denuded coronary rings. 15 The role of endothelium in urocortin effect varied depending on the arteries and apparently on the type of the contraction stimuli. [15] [16] [17] [18] [19] Moreover diverse concentrations of urocortin were used to relax different vessels, which generally were higher than the physiological range described in human plasma membrane. 38 In fact, a full relaxation was induced by 10 nmol/L urocortin in basilar artery 18 ; 10 to 30 nmol/L of urocortin induced maximum relaxation in U46619 precontracted rat coronary and human mammary artery, [15] [16] [17] 100 nmol/L produced 60% relaxation of tail artery precontracted with high K ϩ , 19 meanwhile up to 206 nmol/L of urocortin caused a moderate decrease of coronary perfusion pressure in isolated rat heart. 39 Here we showed that urocortin induced a potent relaxation with an IC 50 Ϸ4.5 nmol/L which is within the range of the relaxation described previously in coronary artery. 15, 16 Furthermore, we presented evidences that urocortin relaxed PE-and TG-activated coronary vasoconstriction by SOCE modulation. Importantly, TG-induced contraction seems to involve SMC depolarization and the consequent coactivation of SOC and L-type Ca 2ϩ channel as it was reported previously in other SMCs. 3, 30 On the other hand, urocortin inhibited TG-induced store operated Ca 2ϩ and Mn 2ϩ influx that we recorded in fresh and primary culture of coronary SMCs. In fact, we confirmed that SOCE is involved in coronary vascular tone regulation. Unfortunately, the progress in the SOCE field has been severely hindered by the absence of relatively specific inhibitors of SOC channels; and despite the lack of specificity of 2APB it remains the most reliable and widely used inhibitor of SOCE. 24, 25 Diethylstilbestrol (DES) which has been demonstrated as more specific inhibitor for SOC channels in SMCs, RBL, and Platelets, 26, 27 inhibited SOCE in coronary SMCs and induced a very potent relaxation of coronary artery with an IC 50 around 260 nmol/L, a very low concentration compared with 30 mol/L that was proposed to inhibit L-type Ca 2ϩ channels in A7r5 cells line. 40 These results supported 2APB effects in coronary artery and ensured that we are targeting SOC pathway.
As reported iPLA 2 activation is absolutely required for the activation of SOC channels and SOCE after depletion of Ca 2ϩ stores. 6 -8,33 Here, we brought new and important data concerning the contribution of iPLA 2 and SOCE on coronary vascular tone. Interestingly, urocortin inhibited the activity of iPLA 2 in the same way as iPLA 2 antisense and BEL as described. 6, 8, 33 This inhibition suggests that the decrease of iPLA 2 products will shut down the Ca 2ϩ influx through SOC channels. Importantly in presence of urocortin LPC and LPI, iPLA 2 products, evoked exactly the same 2APB sensitive Figure 6 . Urocortin activates PKA, inhibits iPLA 2 activity, and induces relaxation via a PKA-dependent mechanism. A, Bar graph showing the activity of PKA in untreated arterial rings (control); in rings stimulated 5 minutes with urocortin (10 nmol/L, Ucn); in arteries incubated 5 minutes with PE (1 mmol/L) and then 5 minutes with urocortin (10 nmol/L, PeϩUcn); and in rings treated 15 minutes with KT5720 (1 mol/L) and incubated 5 minutes with PE (1 mmol/L) then 5 minutes with urocortin (10nmol/L) (KTϩPeϩUcn). nϭ9 samples from 3 separate experiments. B, Average activity of iPLA 2 in SMCs treated with TG (5 mol/L) for 10 minutes to deplete the stores in control cells (TG), in cells pretreated 10 minutes with Urocortin (100 nmol/L, ϩUcn); in cells treated 15 minutes with KT5720 (1 mol/L) followed by 10 minutes Urocortin (100 nmol/L, KTϩUcn); and in cells where db-cAMP was applied 5 minutes (500 mol/L, ϩdb-cAMP). Activity is normalized to total activity in control SMCs. nϭ3 cultures. C, Representative recording and average data of the isometric tension showing that KT5720 (1 mol/L) prevent urocortin (10 nmol/L) but not BEL (25 mol/L) relaxation of PE-(1 mmol/L) induced contractions. The bar graphs represent the meanϮSEM tension expressed in percent of resting tension in each ring (nϭ7). SOCE as in control SMCs demonstrating that even when functional activity of iPLA 2 is inhibited with urocortin its downstream products are capable of activating SOCE in SMCs. The ability of lysophospholipids to activate SOCE in the presence of urocortin ruled out any possibility that urocortin could be inhibiting SOC channels directly. Lysophospholipid activation of SOCE was originally proposed in SMCs and RBL cells 7 and now are shown to activate SOC channels in rat cerebellar astrocytes 34 and some TRP channels in prostate and in Human saphenous vein SMCs. 35, 41 Furthermore, we established that urocortin via the activation CRF-R 2 , stimulated cAMP/PKA pathway. 11, 12, 20 Therefore we showed that db-cAMP mimicked the effects of urocortin and inhibited iPLA 2 activity and SOCE as well as it relaxed TG-and PE-induced vasoconstriction; meanwhile we determined that urocortin regulation of iPLA 2 activity, SOCE, and contractions are mediated by PKA. The precise mechanism(s) by which urocortin modulates iPLA 2 through PKA remains to be determined, but it is known that iPLA 2 possesses numerous potential sites for phosphorylation and its modulation by protein kinase has been proposed in coronary endothelial cells. 42 Our interests in demonstrating that urocortin could modulate iPLA 2 take us to a very intriguing outcome. Indeed, besides its acute effect on iPLA 2 activation we found that urocortin downregulated iPLA 2 expression. Real-time quantitative PCR, Western blot, and immunohistochemistry results showed that urocortin modulated iPLA 2 expressions in coronary SMCs similar to that described in cardiomyocytes. 13 Here, we gave new data and proof demonstrating that these effects can be observed also in SMCs and are dependent on a mechanism involving cAMP and PKA. The downregulation of iPLA 2 by urocortin can be of major interest, as iPLA 2 is known to participate in several important cell processes such as ischemia/reperfusion syndrome, cellular remodeling, and cell cycle progression. 13, 14, 43, 44 In summary, our results add further confirmations of the crucial role of the store-operated pathway and iPLA 2 in the regulation of vascular tone and establish iPLA 2 as a potential target for different signaling cascade as the one that involves urocortin, cAMP, and PKA. Independent lines of evidence presented here reveal urocortin, via a cAMP/PKA mechanism, as a negative modulator of iPLA 2 activity which leads to the shut down of SOC channels, the inhibition of Ca 2ϩ influx that provokes a vasodilatation of rat coronary artery as summarized in Figure 8 . We believe that this novel finding may provide a new molecular basis for developing new therapeutic agents for cardiovascular diseases associated with iPLA 2 modulation and Ca 2ϩ regulation of vasoconstriction. Figure 8 . A proposed model for the "on" and "off" mechanism of SOC in SMCs. The blue lines show the "on" mechanism, where an agonist as PE binds to its receptor, triggers InsP 3induced Ca 2ϩ release, depletion of the stores, activation of iPLA 2 , SOC opening, and then Ca 2ϩ entry which triggers the contraction of the coronary artery. The red lines propose the "off" mechanism where Urocortin binds its receptor CRF-R 2 , stimulates the cAMP production and PKA activation, that provokes the inhibition of iPLA 2 , and in consequence the SOC closing which lead to vascular relaxation.
